Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can allergy med stop bone pain in stem cell transplants?

NCT ID NCT05421416

First seen Feb 05, 2026 · Last updated Jun 19, 2026 · Updated 17 times

Summary

This study tests whether the allergy drug loratadine can prevent bone pain caused by G-CSF, a medicine used to collect stem cells for transplant. About 78 adults with lymphoma or multiple myeloma will receive either loratadine or a placebo. The goal is to see if loratadine reduces pain severity and daily-life interference.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cross Cancer Institute

    RECRUITING

    Edmonton, Alberta, T6G 1Z2, Canada

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Loratadine

What this could lead to

If it works, this could offer a simple, over-the-counter way to prevent bone pain during stem cell collection.

What could go wrong

This is a small, early-phase trial with only 78 participants, so results may not apply widely. Loratadine may not reduce pain better than a placebo.

Conditions

The condition(s) this trial relates to.

disease related to hematopoietic stem cell transplant lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.